Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV)
Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV)
复制标题
DOI：
10.1006/scbi.1998.0089
复制
发表时间：
1999-06-01
影响因子：
14.5
通讯作者：
Ablashi, DV
中科院分区：
文献类型：
--
作者：
Chatlynne, LG;Ablashi, DV
因为卡波西肉瘤相关疱疹病毒（KSHV也被称为HHV-8，人类疱疹病毒-8）被浸渍覆盖，已经表明该病毒与卡波西肉瘤（KS）经典的、地方性的或AIDS相关的所有病例相关。在已经研究该病毒的血清阳性率的许多国家中，数据表明该病毒并不像其它人类疱疹病毒那样普遍存在于一般健康人群中。许多血清阳性率的研究，以检测抗体HHV-8现在已经进行了各种免疫技术。虽然这些检测不完全一致，可能高估或低估一般人群中血清的阳性率，但它们都显示出相似的一般抗体趋势。对于一般人群，撒哈拉以南非洲的血清阳性率最高，约为40%;地中海国家的血清阳性率约为10%;而北方欧洲、东南亚和加勒比海国家的血清阳性率在2-4%范围内。在美国，一个“混合碗”县的血清阳性率在5- 20%的范围内。在患有KS的人中，无论是AIDS相关的经典疾病，还是地方病和其他HHV-8相关疾病，如多中心Castleman病和某些体腔淋巴瘤（BCL），也称为原发性渗出性淋巴瘤（PEL），血清阳性率> 90%。在HIV-1感染但未诊断出KS的人群中，血清阳性率高于一般人群（20-50%），但东南亚和加勒比地区除外，在这些地区未报告AIDS相关的KS。KSHV抗体的存在与其他恶性肿瘤之间没有相关性。
Since the Kaposi's sarcoma-associated herpesvirus (KSHV also referred to as HHV-8, human herpesvirus-8) was dip covered it has been shown that the virus is associated with all cases of Kaposi's sarcoma (KS) classical, endemic, or AIDS associated, In the numerous countries where the seroprevalence of this virus has been studied, data demonstrate that the virus is not ubiquitous in general healthy human populations as is the case with other human herpesviruses. Many seroprevalence studies to detect antibodies to HHV-8 have now been conducted using a variety of immunologic techniques. While these assays are not in total agreement and may overstate or understate the positivity of sera in the general population, they all show similar general antibody trends. For general populations the seroprevalance in sub-Saharan Africa is the highest, approximately 40% positive; in Mediterranean countries the seroprevalance is approximately 10%; whereas northern European, southeast Asian, and Caribbean countries have seroprevalence rates in the 2-4% range. In the United States, a 'mixing bowl' county the seroprevalence is in the range of 5-20%. In people with KS whether AIDS associated classical, or endemic and other HHV-8 associated diseases such as multicentric Castleman's disease and certain body cavity lymphomas (BCL), also called primary effusion lymphoma (PEL) the seroprevalency rates are >90%. In populations with HIV-1 infection but no diagnosis of KS, the seroprevalency rates are elevated (20-50%) above those in the general population except in southeast Asia and the Caribbean where no AIDS associated KS has been reported. No correlation has been found between the presence of KSHV antibodies and other malignancies.